Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's 'Haphazard' Ban On 344 Combos Struck Down But Will Science Prevail?

Executive Summary

An Indian court has struck down a controversial government order aimed at weeding out over 300 irrational fixed dose combinations, bringing some relief to the pharma industry, although the case seems far from over. The jury appears to be still out on the therapeutic rationale of some of the combinations, raising questions around patient interests.

You may also be interested in...



India Recommendation To Ban Irrational Drugs – Science Prevails But Calls To Go The Whole Hog

An Indian expert panel has recommended prohibiting over 300 "irrational" fixed dose combinations, reinforcing a previous ban on such products. Some stakeholders want such weeding out to be an ongoing exercise alongside fool-proofing the regulatory system.

India Pharma 2017: 3Cs And D (Disruption)?

2017 is predicted to be action-packed for the Indian pharmaceutical industry. Compliance-related issues, consolidation, a potential pick-up in collaborations between innovator and local firms, and activity around Indian biosimilars on the global stage, are just some of the things to keep an eye out for. Meanwhile, India’s demonetization move and the Trump presidency will be reminders to expect the unexpected, say experts.

India Pharma 2017: 3Cs And D (Disruption)?

2017 is predicted to be action-packed for the Indian pharmaceutical industry. Compliance-related issues, consolidation, a potential pick-up in collaborations between innovator and local firms, and activity around Indian biosimilars on the global stage, are just some of the things to keep an eye out for. Meanwhile, India’s demonetization move and the Trump presidency will be reminders to expect the unexpected, say experts.

Topics

Related Companies

UsernamePublicRestriction

Register

PS119620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel